Top Markets
Coin of the day
Hepion Pharmaceuticals, Inc. Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals, Inc.

HEPA
Classifica tra le azioni #39071
Hepion Pharmaceuticals, Inc., a U.S.-based biopharmaceutical entity, is... Hepion Pharmaceuticals, Inc., a U.S.-based biopharmaceutical entity, is dedicated to developing therapeutic interventions for chronic hepatic ailments. Central to their efforts is Rencofilstat, a cyclophilin inhibitor that has successfully concluded Phase 2a clinical trials. This compound operates by disrupting multiple pathological pathways implicated in the worsening of liver disease. It is currently progressing through clinical development for non-alcoholic steatohepatitis (NASH) and is additionally being explored in nonclinical research for its potential to reduce liver fibrosis and lessen hepatocellular carcinoma tumor loads in experimental models of NASH. Moreover, Rencofilstat has exhibited antiviral properties against hepatitis B, C, and D viruses through diverse mechanisms. The company, established in 2013 and situated in Edison, New Jersey, rebranded as Hepion Pharmaceuticals, Inc. in July 2019, having previously operated as ContraVir Pharmaceuticals, Inc.
Prezzo delle azioni
$0.0568
Ultima sincronizzazione: 2026-08-13
Capitalizzazione di mercato
$661.36K
Variazione (1 giorno)
11.37%
Variazione (1 anno)
-5.33%
Paese
US
Scambia Hepion Pharmaceuticals, Inc. (HEPA)

Categoria

Storico del rendimento da dividendi per Hepion Pharmaceuticals, Inc. (HEPA)
Il rendimento da dividendi (TTM) di Hepion Pharmaceuticals, Inc. (simbolo azionario: HEPA) al 2026 è: 0
Rendimento medio negli ultimi 5 anni: 0.00%
Storico del rendimento da dividendi per Hepion Pharmaceuticals, Inc. (HEPA) da 2026 a 2026
Rendimento da dividendi alla fine di ogni anno (TTM)
Anno Rendimento da dividendi Cambia
Non abbastanza dati per le date fornite.
Rendimenti da dividendi (TTM) di aziende simili o concorrenti
Azienda Rendimento da dividendi Il paese
0.00%
US
0.00%
NL
0.00%
CH
0.00%
KR
0.65%
BE